ArticleClinical case reports2025
Rapidly Progressive Multiple System Atrophy-Cerebellar Type in a 52-Year-Old Woman: Diagnostic Challenges in a Resource-Limited Setting.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapidly Progressive Multiple System Atrophy-Cerebellar Type in a 52-Year-Old Woman: Diagnostic Challenges in a Resource-Limited Setting.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple system atrophy (MSA) is a progressive adult-onset neurodegenerative disorder that manifests as a variable combination of cerebellar, parkinsonian, and autonomic dysfunctions. We report a case of a 52-year-old woman who presented with rapidly progressive gait ataxia, dysarthria, orthostatic hypotension, and urinary urgency. MRI of the brain demonstrated pontocerebellar atrophy with the characteristic "hot cross bun" sign, supporting a diagnosis of Multiple System Atrophy-cerebellar type (MSA-C). Despite receiving levodopa and supportive therapy, the symptoms progressed over 8 months, highlighting the unusually rapid disease course. This case highlights the diagnostic value of targeted clinical assessment and MRI when advanced confirmatory tests are inaccessible, underscoring the importance of early recognition and multidisciplinary symptom management in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.